Pfizer Rx-To-OTC Comments: Study Before You Switch
Executive Summary
FDA should evaluate whether nonprescription Claritin has increased access and lowered costs for allergy sufferers before deciding whether to force the OTC switch of other second-generation antihistamines, Pfizer asserts in May 7 comments to the agency